Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$803.04 +0.7%	$710.80	$510.05 ▼ $807.91	$49.14B	0.46	373,686 shs	226,271 shs
MRK Merck & Co., Inc.	$86.60 -1.2%	$83.06	$73.31 ▼ $111.58	$216.17B	0.37	15.01 million shs	4.77 million shs
SMMT Summit Therapeutics	$23.40 +5.0%	$23.40	$15.55 ▼ $36.91	$17.29B	-1.13	3.78 million shs	1.83 million shs
TAK Takeda Pharmaceutical	$14.34 -0.9%	$14.85	$12.80 ▼ $15.69	$45.61B	0.21	2.60 million shs	1.85 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+1.19%	+8.11%	+6.20%	+43.62%	+52.52%
MRK Merck & Co., Inc.	-1.35%	+4.37%	+3.60%	+4.65%	-19.29%
SMMT Summit Therapeutics	+0.63%	+7.89%	-14.20%	-9.90%	+17.81%
TAK Takeda Pharmaceutical	-0.65%	-1.26%	-6.04%	-4.46%	+0.94%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$803.04 +0.7%	$710.80	$510.05 ▼ $807.91	$49.14B	0.46	373,686 shs	226,271 shs
MRK Merck & Co., Inc.	$86.60 -1.2%	$83.06	$73.31 ▼ $111.58	$216.17B	0.37	15.01 million shs	4.77 million shs
SMMT Summit Therapeutics	$23.40 +5.0%	$23.40	$15.55 ▼ $36.91	$17.29B	-1.13	3.78 million shs	1.83 million shs
TAK Takeda Pharmaceutical	$14.34 -0.9%	$14.85	$12.80 ▼ $15.69	$45.61B	0.21	2.60 million shs	1.85 million shs

A Guide To High-Short-Interest Stocks

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+1.19%	+8.11%	+6.20%	+43.62%	+52.52%
MRK Merck & Co., Inc.	-1.35%	+4.37%	+3.60%	+4.65%	-19.29%
SMMT Summit Therapeutics	+0.63%	+7.89%	-14.20%	-9.90%	+17.81%
TAK Takeda Pharmaceutical	-0.65%	-1.26%	-6.04%	-4.46%	+0.94%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	3.04	Buy	$802.90	-0.02% Downside
MRK Merck & Co., Inc.	2.29	Hold	$104.31	20.45% Upside
SMMT Summit Therapeutics	2.44	Hold	$31.29	33.73% Upside
TAK Takeda Pharmaceutical	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest SMMT, MRK, ARGX, and TAK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2025	ARGX argenex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
10/8/2025	MRK Merck & Co., Inc.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
10/8/2025	SMMT Summit Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/1/2025	ARGX argenex	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$766.00 ➝ $1,040.00
9/27/2025	ARGX argenex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
9/27/2025	MRK Merck & Co., Inc.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
9/27/2025	SMMT Summit Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/27/2025	TAK Takeda Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
9/25/2025	SMMT Summit Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/22/2025	ARGX argenex	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
9/18/2025	ARGX argenex	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$882.00

(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$2.25B	21.82	$3.03 per share	265.26	$90.49 per share	8.87
MRK Merck & Co., Inc.	$64.17B	3.37	$9.23 per share	9.38	$18.33 per share	4.72
SMMT Summit Therapeutics	$700K	24,827.11	N/A	N/A	$0.53 per share	44.14
TAK Takeda Pharmaceutical	$30.09B	1.52	$3.13 per share	4.58	$14.39 per share	1.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$833.04M	$19.50	41.18	74.01	0.86	40.98%	21.06%	18.25%	10/30/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.49	13.34	8.75	0.91	25.79%	41.05%	16.55%	10/30/2025 (Estimated)
SMMT Summit Therapeutics	-$221.32M	-$1.01	N/A	N/A	N/A	N/A	-208.64%	-181.28%	10/29/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.30	47.78	8.69	N/A	3.20%	10.50%	5.10%	10/30/2025 (Estimated)

Latest SMMT, MRK, ARGX, and TAK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/30/2025	Q3 2025	ARGX argenex	$4.34	N/A	N/A	N/A	$909.86 million	N/A
10/30/2025	Q3 2025	MRK Merck & Co., Inc.	$2.37	N/A	N/A	N/A	$17.00 billion	N/A
10/30/2025	Q2 2026	TAK Takeda Pharmaceutical	$0.46	N/A	N/A	N/A	$8.01 billion	N/A
10/29/2025	Q3 2025	SMMT Summit Therapeutics	-$0.15	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	SMMT Summit Therapeutics	-$0.10	-$0.76	-$0.66	-$0.76	N/A	N/A
7/31/2025	Q2 2025	ARGX argenex	$2.84	$3.74	+$0.90	$3.74	$776.82 million	$866.79 million
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	$0.52	+$0.05	$0.27	$7.96 billion	$7.45 billion
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	$2.13	+$0.10	$1.76	$15.92 billion	$15.81 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
MRK Merck & Co., Inc.	$3.24	3.74%	N/A	49.92%	14 Years
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.55	3.84%	N/A	183.33%	N/A

Latest SMMT, MRK, ARGX, and TAK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/22/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4%	9/15/2025	9/15/2025	10/7/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.60	5.27
MRK Merck & Co., Inc.	0.69	1.42	1.17
SMMT Summit Therapeutics	N/A	5.13	5.13
TAK Takeda Pharmaceutical	0.60	1.16	0.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
MRK Merck & Co., Inc.	76.07%
SMMT Summit Therapeutics	4.61%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
MRK Merck & Co., Inc.	0.09%
SMMT Summit Therapeutics	84.90%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,599	61.20 million	59.71 million	Optionable
MRK Merck & Co., Inc.	75,000	2.50 billion	2.50 billion	Optionable
SMMT Summit Therapeutics	110	742.85 million	112.17 million	Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable

SMMT, MRK, ARGX, and TAK Headlines

Recent News About These Companies

Biopharmaceutical company Takeda to lay off more than 130 employees in Cambridge

October 7 at 8:49 AM | wickedlocal.comW

Pharmaceutical Executive Daily: Updated Vaccine Recommendations

October 6 at 8:17 PM | pharmexec.comP

Major pharmaceutical company announces new round of Greater Boston layoffs

October 6 at 8:17 PM | msn.com

Pharma Pulse: FDA Approves First Generic Mifepristone, Takeda Exits Cell Therapy Research, and SciSafe Expands Biopharma Storage

October 6 at 6:24 AM | pharmaceuticalcommerce.comP

Takeda Pharmaceutical Co. $TAK Shares Bought by QRG Capital Management Inc.

October 6 at 4:18 AM | marketbeat.com

Takeda, largest biopharma employer in Mass., announces more layoffs

October 4, 2025 | bostonglobe.comB

With Emma Walmsley exiting GSK, who will be pharma’s top women CEOs?

October 3, 2025 | finance.yahoo.com

Takeda Announces Decision to Discontinue Cell Therapy Research

October 2, 2025 | pharmexec.comP

Takeda walks away from cell therapy in priority U-turn

October 2, 2025 | pharmaceutical-technology.comP

Takeda walks away from cell therapy in priority U-turn

October 2, 2025 | pharmaceutical-technology.comP

Takeda, in reversal, abandons cell therapy research

October 1, 2025 | biopharmadive.comB

Takeda Pharmaceutical unveils $170M expansion in Thousand Oaks

October 1, 2025 | msn.com

Takeda Pharmaceutical to exit cell therapy research

October 1, 2025 | reuters.com

Bristol Myers, Takeda to pool data for AI-based drug discovery

October 1, 2025 | reuters.com

UNOPS and Takeda partner to tackle medical waste crisis in Bangladesh

September 30, 2025 | dhakatribune.comD

Morgan Stanley Reaffirms Their Buy Rating on Takeda Pharmaceutical Co (TKPHF)

September 25, 2025 | theglobeandmail.com

Takeda Announces Financial Reclassification to Enhance Capital Flexibility

September 25, 2025 | msn.com

Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually

September 24, 2025 | seekingalpha.com

20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries

September 23, 2025 | businesswire.com

Pharma Pulse: CDC Delays Hepatitis B Vaccine Vote, Value-Based Care Improves Senior Access, and Takeda Tests Wind-Powered Shipping

September 22, 2025 | pharmaceuticalcommerce.comP

Pharma Pulse: CDC Delays Hepatitis B Vaccine Vote, Value-Based Care Improves Senior Access, and Takeda Tests Wind-Powered Shipping

September 22, 2025 | pharmaceuticalcommerce.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMMT, MRK, ARGX, and TAK Company Descriptions

argenex NASDAQ:ARGX

$800.06 +2.71 (+0.34%)

As of 03:16 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Merck & Co., Inc. NYSE:MRK

$86.66 -0.95 (-1.09%)

As of 03:17 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Summit Therapeutics NASDAQ:SMMT

$23.36 +1.07 (+4.80%)

As of 03:17 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Takeda Pharmaceutical NYSE:TAK

$14.32 -0.14 (-0.93%)

As of 03:16 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SMMT, MRK, ARGX, and TAK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SMMT, MRK, ARGX, and TAK Earnings

Compare Dividends

Latest SMMT, MRK, ARGX, and TAK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SMMT, MRK, ARGX, and TAK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMMT, MRK, ARGX, and TAK Company Descriptions

argenex NASDAQ:ARGX

Merck & Co., Inc. NYSE:MRK

Summit Therapeutics NASDAQ:SMMT

Takeda Pharmaceutical NYSE:TAK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SMMT, MRK, ARGX, and TAK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SMMT, MRK, ARGX, and TAK Earnings

Compare Dividends

Latest SMMT, MRK, ARGX, and TAK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SMMT, MRK, ARGX, and TAK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMMT, MRK, ARGX, and TAK Company Descriptions

argenex NASDAQ:ARGX

Merck & Co., Inc. NYSE:MRK

Summit Therapeutics NASDAQ:SMMT

Takeda Pharmaceutical NYSE:TAK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools